|
KINAXO Biotechnologies announced today a cooperation between Oncovova Therapeutics and KINAXO Biotechnologies
Martinsried, Germany | May 9, 2008 | KINAXO Biotechnologies announced today a cooperation between Oncovova Therapeutics Inc, Newtown, PA, USA (www.onconova.com) and KINAXO Biotechnologies. Onconova Therapeutics is a clinical stage research and development company focused on development of its novel small molecule products for cancer therapy and radiation protection. KINAXO will apply its Cellular Target Profiling Technology to support Onconova’s clinical development of cancer drugs.
KINAXO’s Cellular Target Profiling Technology includes identification of a compound’s cellular target profile as well as affinity data for targets identified from cell lines. It utilizes proprietary chemical proteomics technologies combined with state-of-the-art mass spectrometry to identify and characterize a drug candidate’s native molecular targets in cell lines and tissue samples. The affinity is determined using a free, unmodified compound. This service enables pharmaceutical and biotechnology companies to make more informed decisions on which drug candidates to progress into advanced pre-clinical or clinical development.
About KINAXO
KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. We support pharmaceutical and biotechnology companies in their development and optimization of drugs.
As a spin-off of the Max-Planck Institute of Biochemistry in Martinsried, KINAXO offers extensive experience and a proven track record in cellular kinase profiling with several pharmaceutical and biotechnology company collaborations ongoing, i.e. UCB Pharma, Johnson & Johnson and Takeda. KINAXO is financed by European investors BioM, High-Tech Gründerfonds, KfW, Max Planck Society, and Mountain Partners.
SOURCE: KINAXO Biotechnologies
|
